Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer

Current Oncology Reports

Volumn 12, Issue 2, 2010, Pages 87-94

  Cleary, James M ^a   Shapiro, Geoffrey I ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Drug development; Phosphoinositide 3 kinase; Targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 17 HYDROXYWORTMANNIN; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; CAL 101; CARBOPLATIN; CISPLATIN; ERLOTINIB; GDC 0980; GEFITINIB; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MK 2206; PACLITAXEL; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B INHIBITOR; PWT 458; UNCLASSIFIED DRUG; WORTMANNIN; XL 147; XL 765;

ABDOMINAL PAIN; ADVANCED CANCER; ADVERSE OUTCOME; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ENZYME ACTIVITY; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE DELETION; GLIOBLASTOMA; HUMAN; HYPERGLYCEMIA; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPHOCYTOPENIA; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERIPHERAL EDEMA; PROSTATE CANCER; RASH; REVIEW; SARCOMA; SIDE EFFECT; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 77952243758     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0091-6     Document Type: Review

References (54)

1. JA Engelman L Ji LC Cantley 2006 The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat Rev Genet 7 606 619 10.1038/nrg1879 1:CAS:528:DC%2BD28XmvFCnu7Y%3D 16847462 (Pubitemid 44100518)
2. V Hietakangas SM Cohen 2009 Regulation of tissue growth through nutrient sensing Annu Rev Genet 43 389 410 10.1146/annurev-genet-102108-134815 1:CAS:528:DC%2BD1MXhsF2qtrnF 19694515
3. P Liu H Cheng TM Roberts JJ Zhao 2009 Targeting the phosphoinositide 3-kinase pathway in cancer Nat Rev Drug Discov 8 627 644 10.1038/nrd2926 1:CAS:528:DC%2BD1MXpt1Wgtb4%3D 19644473 This article provides an extremely informative review on the role of PI3K in cancer. It also reviews therapeutic approaches of targeting the PI3K pathway.
4. R Marone V Cmiljanovic B Giese MP Wymann 2008 Targeting phosphoinositide 3-kinase: moving towards therapy Biochim Biophys Acta 1784 159 185 1:CAS:528:DC%2BD1cXptlerug%3D%3D 17997386 This excellent review thoroughly details the development of PI3K inhibitors.
5. S Gupta AR Ramjaun P Haiko Y Wang, et al. 2007 Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice Cell 129 957 968 10.1016/j.cell.2007.03.051 1:CAS:528:DC%2BD2sXmsl2qsLc%3D 17540175 (Pubitemid 46802703)
6. DA Fruman G Bismuth 2009 Fine tuning the immune response with PI3K Immunol Rev 228 253 272 10.1111/j.1600-065X.2008.00750.x 1:CAS:528: DC%2BD1MXhsFGls7vI 19290933
7. TF Franke 2008 PI3K/Akt: getting it right matters Oncogene 27 6473 6488 10.1038/onc.2008.313 1:CAS:528:DC%2BD1cXht12ltLvN 18955974
8. R Amaravadi CB Thompson 2005 The survival kinases Akt and Pim as potential pharmacological targets J Clin Invest 115 2618 2624 10.1172/JCI26273 1:CAS:528:DC%2BD2MXhtVygt7vL 16200194 (Pubitemid 41434384)
9. DA Guertin DM Sabatini 2007 Defining the role of mTOR in cancer Cancer Cell 12 9 22 10.1016/j.ccr.2007.05.008 1:CAS:528:DC%2BD2sXotVyqsr0%3D 17613433 (Pubitemid 47001784)
10. A Carracedo PP Pandolfi 2008 The PTEN-PI3K pathway: of feedbacks and cross-talks Oncogene 27 5527 5541 10.1038/onc.2008.247 1:CAS:528: DC%2BD1cXhtFWiurzF 18794886
11. Y Samuels Z Wang A Bardelli, et al. 2004 High frequency of mutations of the PIK3CA gene in human cancers Science 304 554 10.1126/science.1096502 1:CAS:528:DC%2BD2cXjsVGmsbk%3D 15016963 (Pubitemid 38541907)
12. JA Engelman 2009 Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat Rev Cancer 9 550 562 10.1038/nrc2664 1:CAS:528:DC%2BD1MXovFylsrg%3D 19629070
13. I Martin-Berenjeno B Vanhaesebroeck 2009 PI3K regulatory subunits lose control in cancer Cancer Cell 16 449 450 10.1016/j.ccr.2009.11.017 1:CAS:528:DC%2BC3cXht1eqsLc%3D 19962660
14. P Sujobert V Bardet P Cornillet-Lefebvre, et al. 2005 Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia Blood 106 1063 1066 10.1182/blood-2004- 08-3225 1:CAS:528:DC%2BD2MXntVSms74%3D 15840695 (Pubitemid 41076455)
15. L Zhao PK Vogt 2008 Class I PI3K in oncogenic cellular transformation Oncogene 27 5486 5496 10.1038/onc.2008.244 1:CAS:528:DC%2BD1cXhtFWiur%2FP 18794883
16. BS Jaiswal V Janakiraman NM Kljavin, et al. 2009 Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation Cancer Cell 16 463 474 10.1016/j.ccr.2009.10.016 1:CAS:528:DC%2BC3cXht1eqsbo%3D 19962665
17. JD Carpten AL Faber C Horn, et al. 2007 A transforming mutation in the pleckstrin homology domain of AKT1 in cancer Nature 448 439 444 10.1038/nature05933 1:CAS:528:DC%2BD2sXotFajtbk%3D 17611497 (Pubitemid 47123510)
18. AC Faber D Li Y Song, et al. 2009 Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition Proc Natl Acad Sci U S A 106 19503 19508 10.1073/pnas.0905056106 1:CAS:528:DC%2BD1MXhsFGitrzJ 19850869 This paper demonstrates that combination therapy with PI3K and MEK inhibitors can be effective in EGFR-addicted cancers.
19. JA Engelman K Zejnullahu T Mitsudomi, et al. 2007 MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 1039 1043 10.1126/science.1141478 1:CAS:528:DC%2BD2sXltlOjt7g%3D 17463250 This paper demonstrated that acquired resistance to EGFR inhibitors can arise through MET amplification. The MET overexpression results in PI3K activation. (Pubitemid 46799492)
20. JA Engelman T Mukohara K Zejnullahu, et al. 2006 Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer J Clin Invest 116 2695 2706 10.1172/JCI28656 1:CAS:528:DC%2BD28XhtVKgu7vN 16906227 (Pubitemid 44511633)
21. M Jhawer S Goel AJ Wilson, et al. 2008 PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab Cancer Res 68 1953 1961 10.1158/0008-5472.CAN-07- 5659 1:CAS:528:DC%2BD1cXjtFOhtro%3D 18339877 (Pubitemid 351416582)
22. Y Nagata KH Lan X Zhou, et al. 2004 PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 117 127 10.1016/j.ccr.2004.06.022 1:CAS:528: DC%2BD2cXns1arsr8%3D 15324695 (Pubitemid 39485684)
23. NT Ihle R Williams S Chow, et al. 2004 Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling Mol Cancer Ther 3 763 772 1:CAS:528:DC%2BD2cXls1anu7k%3D 15252137 (Pubitemid 39193758)
24. CJ Vlahos WF Matter KY Hui RF Brown 1994 A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) J Biol Chem 269 5241 5248 1:CAS:528:DyaK2cXjtFGit78%3D 8106507
25. JR Garlich P De N Dey, et al. 2008 A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity Cancer Res 68 206 215 10.1158/0008-5472.CAN-07-0669 1:CAS:528:DC%2BD1cXoslSn 18172313 (Pubitemid 351380122)
26. NT Ihle G Paine-Murrieta MI Berggren, et al. 2005 The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts Mol Cancer Ther 4 1349 1357 10.1158/1535-7163.MCT- 05-0149 1:CAS:528:DC%2BD2MXhtVKnt7nN 16170026
27. A Jimeno DS Hong S Hecker, et al. 2009 Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor J Clin Oncol (Meeting Abstracts) 27 3542
28. K Yu J Lucas T Zhu, et al. 2005 PWT-458, a novel pegylated-17- hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors Cancer Biol Ther 4 538 545 1:CAS:528:DC%2BD28Xitl2rurw%3D 15846106
29. EG Chiorean D Mahadevan WB Harris, et al. 2009 Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors J Clin Oncol (Meeting Abstracts) 27 2558
30. AJ Folkes K Ahmadi WK Alderton, et al. 2008 The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-yl-t hieno[3, 2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer J Med Chem 51 5522 5532 10.1021/jm800295d 1:CAS:528:DC%2BD1cXhtVCmsr7E 18754654
31. AJ Wagner DH Von Hoff PM LoRusso, et al. 2009 A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors J Clin Oncol (Meeting Abstracts) 27 3501
32. D Sarker R Kristeleit KE Mazina, et al. 2009 A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941 J Clin Oncol (Meeting Abstracts) 27 3538
33. P Foster 2007 Potentiating the antitumor effects of chemotherapy with the selective PI3K inhibitor XL147 AACR Meeting Abstracts 2007 C199
34. G Shapiro E Kwak J Baselga, et al. 2009 Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors J Clin Oncol (Meeting Abstracts) 27 3500
35. N Faulkner PM LoRusso T Guthrie, et al. 2009 A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors Mol Cancer Ther 8 C197
36. Wheler JJ, Traynor AM, Bailey HH, et al.: A phase 1 safety and pharmacokinectic (PK) study of the PI3K inhibitor XL147 in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Presented at the American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics. Boston, MA; November 15-19, 2009:B247.
37. P LoRusso B Markman J Tabernero, et al. 2009 A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors J Clin Oncol (Meeting Abstracts) 27 3502
38. S-M Maira 2008 Brueggen J, et al.: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol Cancer Ther 7 1851 1863 10.1158/1535-7163.MCT-08-0017 1:CAS:528:DC%2BD1cXoslCgtb4%3D 18606717
39. PJ Eichhorn M Gili M Scaltriti, et al. 2008 Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235 Cancer Res 68 9221 9230 10.1158/0008-5472.CAN-08-1740 1:CAS:528:DC%2BD1cXhtlOmt73F 19010894
40. AJ Shaywitz KD Courtney A Patnaik LC Cantley 2008 PI3K enters beta-testing Cell Metabolism 8 179 181 10.1016/j.cmet.2008.08.011 1:CAS:528:DC%2BD1cXhtFejurfF 18762017
41. C Billottet VL Grandage RE Gale, et al. 2006 A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16 Oncogene 25 6648 6659 10.1038/sj.onc.1209670 1:CAS:528:DC%2BD28XhtFaks7%2FN 16702948 (Pubitemid 44646192)
42. S Uddin AR Hussain AK Siraj, et al. 2006 Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival Blood 108 4178 4186 10.1182/blood-2006-04-016907 1:CAS:528:DC%2BD28XhtlWqsrjK 16946303 (Pubitemid 44913290)
43. •• Flinn IW, Byrd JC, Furman RR, et al.: Evidence of clinical activity in a phase 1 study of CAL-101, an oral P110δ isoform-selective inhibitor of phosphatidylinositol 3-kinase, in patients with relapsed or refractory B-Cell malignancies. Presented at the 51st American Society of Hematology Annual Meeting. New Orleans, LA: December 5-8, 2009:922. This abstract describes preliminary results showing that single agent CAL-101 has produced several partial responses in B cell malignancies.
44. JJ Gills PA Dennis 2009 Perifosine: update on a novel Akt inhibitor Curr Oncol Rep 11 102 110 10.1007/s11912-009-0016-4 1:CAS:528:DC%2BD1MXltVSlurs%3D 19216841
45. AW Tolcher TA Yap I Fearen, et al. 2009 A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST) ASCO Meeting Abstracts 27 3503
46. SM Brachmann I Hofmann C Schnell, et al. 2009 Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells Proc Natl Acad Sci U S A 106 22299 22304 10.1073/pnas.0905152106 1:CAS:528:DC%2BC3cXmtlagug%3D%3D 20007781 This paper demonstrates that NVP-BEZ235 is effective in HER2 amplified and PIK3CA mutant breast cancer cells. Importantly, it also shows that breast cancer cells with loss of PTEN function are resistant to NVP-BEZ235.
47. ML Sos S Fischer R Ullrich M Peifer JM Heuckmann M Koker, et al. 2009 Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer Proc Natl Acad Sci U S A. 106 18351 6 10.1073/pnas.0907325106 1:CAS:528:DC%2BD1MXhsVWrsbvJ 19805051
48. Ozbay T, Durden DL, Liu T, et al.: In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. Cancer Chemother Pharmacol 2009 Jul 28 (Epub ahead of print).
49. TT Junttila RW Akita K Parsons, et al. 2009 Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 Cancer Cell 15 429 440 10.1016/j.ccr.2009.03.020 1:CAS:528:DC%2BD1MXmvVGitrg%3D 19411071
50. JA Engelman L Chen X Tan, et al. 2008 Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nat Med 14 1351 1356 10.1038/nm.1890 1:CAS:528:DC%2BD1cXhsVWhu7rI 19029981 This paper shows that combined PI3K and MEK inhibition is effective in a RAS mutated model of murine lung cancer.
51. RC Hui AR Gomes D Constantinidou, et al. 2008 The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression Mol Cell Biol 28 5886 5898 10.1128/MCB.01265-07 1:CAS:528:DC%2BD1cXhtF2gt73E 18644865
52. SSW Ng MS Tsao S Chow DW Hedley 2000 Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells Cancer Res 60 5451 5455 1:CAS:528:DC%2BD3cXns1ehtrw%3D 11034087
53. KM Vasudevan DA Barbie MA Davies, et al. 2009 AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer Cancer Cell 16 21 32 10.1016/j.ccr.2009.04.012 1:CAS:528:DC%2BD1MXhtVWnsL7M 19573809
54. L Toral-Barza WG Zhang C Lamison, et al. 2005 Characterization of the cloned full-length and a truncated human target of rapamycin: activity, specificity, and enzyme inhibition as studied by a high capacity assay Biochem Biophys Res Commun 332 304 310 10.1016/j.bbrc.2005.04.117 1:CAS:528: DC%2BD2MXkt1OjtL4%3D 15896331 (Pubitemid 40719487)